Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Spyre Therapeutics, Inc. (SYRE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Spyre is a clinical-stage biotechnology company listed on the Nasdaq Global Select Market, and its filings document material events, financing activities, and key clinical development updates related to its long-acting antibody programs for inflammatory bowel disease and rheumatic diseases.
Recent Form 8-K reports describe, for example, interim Phase 1 results for SPY003, an investigational extended half-life antibody targeting the p19 subunit of IL-23, including safety and pharmacokinetic findings that the company states support potential quarterly or twice-yearly maintenance dosing. Other 8-K filings detail the initiation and structure of the SKYLINE Phase 2 platform trial in ulcerative colitis and the SKYWAY Phase 2 basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, as well as financial results and preliminary cash balances for specific quarters.
Spyre’s filings also include disclosures about public equity offerings under its shelf registration statement on Form S-3. An 8-K dated October 15, 2025, for example, outlines the terms of an underwritten public offering of common stock, gross proceeds, and the company’s stated intention to use net proceeds to advance programs in IBD and rheumatic diseases, support preclinical and clinical work, manufacturing, and Phase 3 readiness activities, and provide working capital.
On Stock Titan, users can review these filings in sequence and use AI-powered tools to summarize lengthy documents, highlight key sections, and quickly identify items related to clinical data, financing, and other material events disclosed by Spyre Therapeutics.
Morgan Stanley Smith Barney LLC filed a Form 144 disclosing proposed sales of 60,000 common shares of SYRE, linked to previously exercised stock options dated 06/15/2023. The filing records completed 10b5-1 sales of 15,000 shares on 01/02/2026 and 15,000 shares on 02/02/2026, with proceeds of $460,114.50 and $492,069.00, respectively.
Spyre Therapeutics, Inc. deregistered the unsold securities from its Form S-3 shelf registration by filing Post-Effective Amendment No. 1 on February 27, 2026. The original Registration Statement No. 333-285341 had provided for offerings of up to $500,000,000 in securities and up to $179,059,869 of common stock under a TD Securities sales agreement; the company states it has terminated all offerings and removes any securities still unsold from registration.
Spyre Therapeutics, Inc. files a shelf registration to offer up to $500,000,000 of common stock, preferred stock, debt securities, warrants and/or units pursuant to a base prospectus dated February 19, 2026.
The prospectus supplement states an at-the-market sales agreement with TD Cowen to sell up to $154,059,875 of common stock under the Sales Agreement; Nasdaq last sale price was $36.60 per share on February 18, 2026.
This shelf allows multiple offering methods and will be used for working capital, R&D, potential in-licensing or acquisitions, and general corporate purposes; offering specific terms and proceeds treatment will be set in prospectus supplements.
Spyre Therapeutics reported fourth quarter and full year 2025 results and highlighted progress across its IBD and rheumatic disease pipeline. The company is running two Phase 2 trials: the SKYLINE platform study in ulcerative colitis and the SKYWAY basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, with six proof-of-concept readouts planned in 2026.
As of December 31, 2025, Spyre held $756.5 million in cash, cash equivalents, and marketable securities and expects this to fund operations into the second half of 2028. Fourth quarter 2025 R&D expenses were $44.6 million, down from $50.5 million a year earlier, while G&A expenses rose to $12.5 million from $10.8 million.
Other expense in the quarter was $5.4 million, mainly from changes in a contingent value right liability, leading to a quarterly net loss of $62.5 million versus $56.3 million in 2024. For full year 2025, net loss was $155.2 million, compared with $208.0 million in 2024. Spyre also strengthened its balance sheet with an October 2025 underwritten public offering that generated $316.2 million in gross proceeds before $19.8 million in discounts and offering costs.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases. Its core monoclonal antibodies target α4β7 (SPY001), TL1A (SPY002 and SPY072), and IL‑23 (SPY003), including fixed-dose combinations SPY120, SPY130, and SPY230.
The company is running the SKYLINE Phase 2 platform trial in ulcerative colitis and the SKYWAY Phase 2 basket trial of SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, with multiple data readouts expected in 2026 and 2027. Spyre reported approximately $1.1 billion aggregate market value of non‑affiliate equity as of June 30, 2025 and had 78,540,164 common shares outstanding as of February 12, 2026.
Tang Capital Management, Kevin Tang and related funds report a 2.4% passive stake in Spyre Therapeutics, Inc. common stock. They disclose beneficial ownership of 1,892,200 shares, with no sole voting or dispositive power and shared authority over all reported shares.
The group notes that Spyre had 77,592,130 shares outstanding as of October 29, 2025 to calculate this percentage. They also certify the shares were not acquired, and are not held, to change or influence control of Spyre Therapeutics.
Spyre Therapeutics, Inc.'s Chief Executive Officer and director Turtle Cameron reported two open-market sales of common stock. On February 2, 2026, Cameron sold 957 shares at a weighted average price of $31.82 and 14,043 shares at a weighted average price of $32.87, both coded as open-market sales.
The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on June 20, 2025. After these sales, Cameron beneficially owned 657,540 shares of common stock, which include shares scheduled to vest over approximately one year and shares acquired under the company’s employee stock purchase plan.
Spyre Therapeutics, Inc. director Michael Thomas Henderson reported receiving 63,227 shares of common stock on January 21, 2026. The shares were received for no cash consideration through a pro-rata distribution from a limited liability company in which he is a member, rather than through an open-market purchase. Following this distribution, he beneficially owns 168,606 shares of Spyre Therapeutics common stock in direct form.